Lipe & Dalton’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.27M | Sell |
9,883
-145
| -1% | -$17K | 0.59% | 42 |
|
|
2026
Q1 | $1.21M | Buy |
10,028
+5
| +0% | +$577 | 0.63% | 41 |
|
|
2025
Q4 | $1.05M | Sell |
10,023
-346
| -3% | -$32.5K | 0.52% | 45 |
|
|
2025
Q3 | $870K | Sell |
10,369
-297
| -3% | -$24.5K | 0.43% | 50 |
|
|
2025
Q2 | $844K | Sell |
10,666
-196
| -2% | -$15.6K | 0.46% | 49 |
|
|
2025
Q1 | $975K | Sell |
10,862
-697
| -6% | -$65.1K | 0.55% | 50 |
|
|
2024
Q4 | $1.15M | Sell |
11,559
-348
| -3% | -$35.9K | 0.61% | 47 |
|
|
2024
Q3 | $1.35M | Sell |
11,907
-22
| -0.2% | -$2.61K | 0.68% | 46 |
|
|
2024
Q2 | $1.48M | Buy |
11,929
+2
| +0% | +$258 | 0.79% | 40 |
|
|
2024
Q1 | $1.57M | Buy |
11,927
+102
| +0.9% | +$12.6K | 0.81% | 40 |
|
|
2023
Q4 | $1.29M | Buy |
11,825
+2
| +0% | +$208 | 0.7% | 42 |
|
|
2023
Q3 | $1.22M | Buy |
11,823
+1
| +0% | +$108 | 0.73% | 43 |
|
|
2023
Q2 | $1.36M | Buy |
11,822
+1
| +0% | +$114 | 0.78% | 41 |
|
|
2023
Q1 | $1.26M | Sell |
11,821
-150
| -1% | -$16.2K | 0.72% | 41 |
|
|
2022
Q4 | $1.33M | Buy |
11,971
+1
| +0% | +$102 | 0.76% | 40 |
|
|
2022
Q3 | $1.03M | Buy |
11,970
+3,450
| +40% | +$308K | 0.65% | 45 |
|
|
2022
Q2 | $777K | Buy |
8,520
+3,000
| +54% | +$266K | 0.45% | 53 |
|
|
2022
Q1 | $453K | Buy |
5,520
+500
| +10% | +$39.4K | 0.22% | 62 |
|
|
2021
Q4 | $385K | Buy |
5,020
+475
| +10% | +$37.8K | 0.18% | 68 |
|
|
2021
Q3 | $341K | Hold |
4,545
| – | – | 0.18% | 65 |
|
|
2021
Q2 | $353K | Buy |
4,545
+1,039
| +30% | +$77.3K | 0.18% | 65 |
|
|
2021
Q1 | $258K | Buy |
3,506
+1,063
| +44% | +$78.4K | 0.14% | 69 |
|
|
2020
Q4 | $191K | Sell |
2,443
-661
| -21% | -$50.6K | 0.12% | 72 |
|
|
2020
Q3 | $246K | Hold |
3,104
| – | – | 0.17% | 65 |
|
|
2020
Q2 | $229K | Sell |
3,104
-210
| -6% | -$15.8K | 0.17% | 66 |
|
|
2020
Q1 | $243K | Sell |
3,314
-209
| -6% | -$16.4K | 0.21% | 62 |
|
|
2019
Q4 | $306K | Buy |
3,523
+115
| +3% | +$9.45K | 0.2% | 62 |
|
|
2019
Q3 | $274K | Hold |
3,408
| – | – | 0.2% | 65 |
|
|
2019
Q2 | $273K | Hold |
3,408
| – | – | 0.2% | 60 |
|
|
2019
Q1 | $270K | Hold |
3,408
| – | – | 0.2% | 59 |
|
|
2018
Q4 | $248K | Buy |
3,408
+681
| +25% | +$48.1K | 0.2% | 56 |
|
|
2018
Q3 | $185K | Sell |
2,727
-52
| -2% | -$3.31K | 0.13% | 62 |
|
|
2018
Q2 | $161K | Buy |
2,779
+173
| +7% | +$9.76K | 0.12% | 62 |
|
|
2018
Q1 | $135K | Buy |
2,606
+10
| +0.4% | +$540 | 0.1% | 67 |
|
|
2017
Q4 | $139K | Hold |
2,596
| – | – | 0.1% | 66 |
|
|
2017
Q3 | $159K | Buy |
2,596
+1
| +0% | +$61 | 0.11% | 63 |
|
|
2017
Q2 | $159K | Sell |
2,595
-315
| -11% | -$19.2K | 0.1% | 67 |
|
|
2017
Q1 | $176K | Sell |
2,910
-323
| -10% | -$19.6K | 0.13% | 63 |
|
|
2016
Q4 | $182K | Buy |
+3,233
| New | +$189K | 0.13% | 64 |
|
|
2016
Q3 | – | Sell |
-3,232
| Closed | -$178K | – | 86 |
|
|
2016
Q2 | $178K | Hold |
3,232
| – | – | 0.12% | 88 |
|
|
2016
Q1 | $163K | Buy |
3,232
+210
| +7% | +$10.3K | 0.13% | 65 |
|
|
2015
Q4 | $152K | Buy |
+3,022
| New | +$152K | 0.12% | 65 |
|
|
2014
Q3 | – | Sell |
-4,636
| Closed | -$256K | – | 65 |
|
|
2014
Q2 | $256K | Hold |
4,636
| – | – | 0.16% | 50 |
|
|
2014
Q1 | $243K | Buy |
+4,636
| New | +$240K | 0.16% | 51 |
|
Other funds holding MRK
Lipe & Dalton's MRK Position: Q2 2026 in Review
Lipe & Dalton reduced its Merck (MRK) stake by 1.4% in Q2 2026, selling an estimated $17K and leaving 9,883 shares worth $1.27M. The position accounts for 0.59% of the portfolio, ranked #42.
Lipe & Dalton first reported a position in MRK in Q1 2014 and has held it in 44 quarters since. The position peaked at $1.57M in Q1 2024. 3,824 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Lipe & Dalton held 9,883 shares of Merck worth $1.27M as of Q2 2026.
- Lipe & Dalton sold 145 Merck shares in Q2 2026, an estimated $17K.
- Merck made up 0.59% of Lipe & Dalton's portfolio in Q2 2026, its #42 holding.
- Lipe & Dalton first reported a position in Merck in Q1 2014 and has held it in 44 quarters since.
- Lipe & Dalton's Merck position peaked at $1.57M in Q1 2024.
- 3,824 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Lipe & Dalton's 13F filing for Q2 2026, filed 14 Jul 2026.